tradingkey.logo
tradingkey.logo
Suchen

Scinai Immunotherapeutics Ltd

SCNI
Zur Watchlist hinzufügen
0.270USD
-0.001-0.29%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
956.00KMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Scinai Immunotherapeutics Ltd Unternehmen

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Scinai Immunotherapeutics Ltd Informationen

BörsenkürzelSCNI
Name des UnternehmensScinai Immunotherapeutics Ltd
IPO-datumJun 07, 2007
CEOReichman (Amir)
Anzahl der mitarbeiter31
WertpapierartDepository Receipt
GeschäftsjahresendeJun 07
AddresseJerusalem Biopark, 2Nd Floor
StadtJERUSALEM
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl00000
Telefon97289302529
Websitehttps://www.scinai.com/
BörsenkürzelSCNI
IPO-datumJun 07, 2007
CEOReichman (Amir)

Führungskräfte von Scinai Immunotherapeutics Ltd

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
400.02M
+100.00%
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
4.87K
+73.89%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
1.18K
+76.63%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-36.00%
Dr. Yael Margolin
Dr. Yael Margolin
External Director
External Director
50.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
--
Mr. Samuel J. Moed
Mr. Samuel J. Moed
Director
Director
--
--
Dr. Morris C. Laster, M.D.
Dr. Morris C. Laster, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
400.02M
+100.00%
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
4.87K
+73.89%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
1.18K
+76.63%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-36.00%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Scinai Immunotherapeutics Ltd?

Die fünf größten Anteilseigner von Scinai Immunotherapeutics Ltd sind: Mr. Amir Reichman

Wie viele Institutionen halten Anteile an Scinai Immunotherapeutics Ltd (SCNI)?

Mit Stand vom 2026Q1 halten 23 Institutionen Anteile an Scinai Immunotherapeutics Ltd, mit einem Gesamtmarktwert von etwa 179.71K, was 5.08% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 33890.00 gestiegen.